CMS certification 453301
Driscoll Childrens Hospital
3533 S Alameda, Corpus Christi, TX 78411
This page brings together federal quality data for this hospital: its CMS star rating, patient survey results, emergency department times, and death, complication, infection and readmission rates, each compared with the national rate. Everything here comes from CMS and NPPES, the federal sources themselves - not from us.
What patients said
Answers from patients who stayed here, collected by CMS in the national HCAHPS survey: Oct 2024 – Sep 2025.
Not reported for this hospital
CMS had too few cases here to publish results for deaths, complications, infections caught in the hospital, readmissions and return visits. That is common at small, rural and specialty hospitals, and says nothing either way about quality.
Clinicians registered at this address
424 clinicians give this hospital's street address as their practice location in NPPES, the federal provider registry, plus 69 residents and trainees. The same address can take in offices and clinics in the building, and a listing does not prove admitting privileges or current employment.
| Specialty | Clinicians |
|---|---|
| Pediatrics | 62 |
| Speech-Language Pathologist | 62 |
| Dietitian, Registered | 23 |
| Family | 23 |
| Physical Therapist | 21 |
| Occupational Therapist | 16 |
| Anesthesiology | 14 |
| Clinical | 11 |
| Pediatric Critical Care Medicine | 11 |
| Neonatal | 10 |
| Audiologist | 9 |
| Pediatric Anesthesiology | 9 |
First 12 alphabetically
Money from drug and device companies
Drug and device makers have to report what they pay teaching hospitals to CMS's Open Payments program. At many teaching hospitals most of it is research funding, or royalties for inventions the hospital licensed to a company. A payment on its own does not show a conflict of interest.
- 2019 $12,122
- 2020 $413,120
- 2021 $1.5M
- 2022 $1.3M
- 2023 $848,997
- 2024 $635,493
- 2025 $422,317
What the 2025 general payments were for
| Type of payment | Amount | Payments |
|---|---|---|
| Medical devices and supplies on long-term loan | $6,263 | 4 |
| Space rental and facility fees | $4,900 | 5 |
| Speaking, teaching and other services | $1,500 | 1 |
| Grants | $1,500 | 1 |
| Debt forgiveness | $700 | 1 |
| Gifts | $595 | 1 |
Largest paying companies, 2025
| Company | Amount | Payments |
|---|---|---|
| Eli Lilly and Company | $229,251 | 9 |
| Amgen Inc. | $95,497 | 4 |
| Pfizer INC. | $51,283 | 13 |
| Sanofi US Services INC. | $20,651 | 5 |
| Merck Sharp & Dohme LLC | $10,329 | 3 |
| Stryker Corporation | $6,964 | 5 |
| Insulet Corporation | $1,500 | 1 |
| Tandem Diabetes Care, Inc. | $1,500 | 1 |
Largest research studies funded here, 2025
| Study | Amount |
|---|---|
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR THE TREATMENT OF OBESITY AND WEIGHT-RELATED COMORBIDITIES IN ADOLESCENTS: A RANDOMI… Eli Lilly and Company · NCT06439277 | $211,618 |
| A Phase 3b, Multi Center, Open-label, Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Mo… Amgen Inc. | $52,547 |
| A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent… Amgen Inc. | $36,650 |
| A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CH… PFIZER INC. | $31,961 |
| A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants >=6 Months to <18 Years of Age With Prurig… SANOFI US SERVICES INC. · NCT06293053 | $20,651 |
| A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS T… PFIZER INC. | $19,322 |
| A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654… Merck Sharp & Dohme LLC | $9,529 |
| A Phase 3, Open-label, 52-week Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab (AMG 451) in Adolescent Subjects Aged ? 12 to <… Amgen Inc. | $6,300 |
Amounts are as the paying companies reported them to CMS; Open Payments data retrieved 13 Sep 2026. Full record on CMS Open Payments.
How to read this page
- Everything here is published by CMS on Care Compare. We arrange it and explain it; the star ratings and the better / worse verdicts are CMS's, not ours.
- “No different” is the most common result on most measures at most hospitals. CMS only calls a result better or worse when the difference from the national rate is statistically clear.
- Death, complication and readmission rates are adjusted by CMS for how sick patients were, so hospitals that treat sicker patients can be compared fairly.
- Infection results are ratios: 1.0 means as many infections as CMS predicted for a hospital like this one, below 1.0 is fewer.
- These are hospital-wide results. They do not rate an individual doctor, nurse or department, and they are not medical advice.
CMS Care Compare data retrieved 4 Oct 2026, refreshed weekly. Where this data comes from and how we handle it · Report an error
Common questions about Driscoll Childrens Hospital
Does Driscoll Childrens Hospital have an emergency room?
Yes. CMS lists emergency services at Driscoll Childrens Hospital.
Does Driscoll Childrens Hospital receive money from drug and device companies?
Drug and device makers reported $422,317 in payments to Driscoll Childrens Hospital for 2025, most of it research funding, under the federal Open Payments program. A payment on its own does not show a conflict of interest.